These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 27078238)
41. A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome. Mansour NM; Ghaith O; El-Halabi M; Sharara AI Am J Gastroenterol; 2012 May; 107(5):792-3. PubMed ID: 22552247 [No Abstract] [Full Text] [Related]
42. A review of irritable bowel syndrome and an update on therapeutic approaches. Bassett JT; Cash BD Expert Opin Pharmacother; 2008 May; 9(7):1129-43. PubMed ID: 18422471 [TBL] [Abstract][Full Text] [Related]
43. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. Dumitrascu DL; Chira A; Bataga S; Diculescu M; Drug V; Gheorghe C; Goldis A; Nedelcu L; Porr PJ; Sporea I; J Gastrointestin Liver Dis; 2014 Dec; 23(4):431-5. PubMed ID: 25532003 [No Abstract] [Full Text] [Related]
44. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Chang L; Lembo A; Sultan S Gastroenterology; 2014 Nov; 147(5):1149-72.e2. PubMed ID: 25224525 [No Abstract] [Full Text] [Related]
45. By the way, doctor. I have irritable bowel syndrome, with frequent bloating and constipation. My doctor prescribed a six-week course of Zelnorm, which really helped. Is it safe to take long-term? Robb-Nicholson C Harv Womens Health Watch; 2005 May; 12(9):8. PubMed ID: 16047399 [No Abstract] [Full Text] [Related]
46. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656 [TBL] [Abstract][Full Text] [Related]
49. Rifaximin (Xifaxan) for Irritable Bowel Syndrome. Karuppiah S; Pomianowski K Am Fam Physician; 2017 Feb; 95(4):258-259. PubMed ID: 28290635 [No Abstract] [Full Text] [Related]
50. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Weinberg DS; Smalley W; Heidelbaugh JJ; Sultan S; Gastroenterology; 2014 Nov; 147(5):1146-8. PubMed ID: 25224526 [No Abstract] [Full Text] [Related]
51. [Meteospazmil for correction of motor disorders in functional colon diseases]. Agafonova NA; Iakovenko EP; Ivanov AN; Prianishnikova AS; Iakovenko AV Eksp Klin Gastroenterol; 2009; (4):101-6. PubMed ID: 19961001 [TBL] [Abstract][Full Text] [Related]
52. [Clinical practice guideline for irritable bowel syndrome]. Tort S; Balboa A; Marzo M; Carrillo R; Mínguez M; Valdepérez J; Alonso-Coello P; Mascort JJ; Ferrándiz J; Bonfill X; Piqué JM; Mearin F; ; ; Gastroenterol Hepatol; 2006 Oct; 29(8):467-521. PubMed ID: 17020681 [No Abstract] [Full Text] [Related]
56. FDA approves one drug for irritable bowel syndrome but suspends another. Harv Womens Health Watch; 2008 Aug; 15(12):7. PubMed ID: 19115501 [No Abstract] [Full Text] [Related]
57. New drug for bothersome bowels. Health News; 2000 Apr; 6(4):8. PubMed ID: 15356893 [No Abstract] [Full Text] [Related]